What question did this study set out to answer?

The study aims to evaluate the potential of paraxanthine and azilsartan in treating gentamicin-induced renal fibrosis.

May 13, 2026Journal of Translational Medicine0 citationsOpen Access

Paraxanthine and azilsartan attenuate gentamicin-induced renal fibrosis via modulation of TGF-β1/Smad3/7 signaling and miRNA-21/miRNA-200b expression

NENany Saad Rizk El-AdwyTanta University NENahla E. El-AshmawyBritish University in Egypt GAGhada M. Al-AshmawyCairo University

Key Points

The study aims to evaluate the potential of paraxanthine and azilsartan in treating gentamicin-induced renal fibrosis.
Seventy male albino mice were randomized into seven groups.
Gentamicin was administered for 7 days at 40 mg/kg.
Paraxanthine (20.5 mg/kg) and azilsartan (5 mg/kg) were given orally after gentamicin treatment.
Histopathological analysis and gene expression of relevant markers were conducted.
Serum and urine renal function markers were measured.
Gentamicin caused significant nephrotoxicity with elevated serum creatinine and BUN.
Treatment with paraxanthine and azilsartan improved renal functions significantly.
Pro-fibrotic markers such as TGF-β1 and type I collagen were reduced in treated groups.
MiRNA-21 was downregulated while miRNA-200b was upregulated following treatments.

Abstract

Abstract Background Renal fibrosis is a key contributor to chronic kidney disease progression. The TGF-β1/Smad signaling pathway, particularly Smad2 and Smad3 mediate pro-fibrotic responses, while Smad7 exerts inhibitory effects. Aim The study aimed to evaluate the therapeutic potential of paraxanthine (Para), an active caffeine metabolite, and azilsartan (Azil), an angiotensin II receptor blocker, in attenuating gentamicin (GM)-induced renal fibrosis through targeting Smad pathway and miRNA-21/200b. Methods Seventy male albino mice were randomized into seven groups ( n = 10): Control, GM, SIS3 + GM, Para + GM, Azil + GM, Para + SIS3 + GM, and Azil + SIS3 + GM. GM (40 mg/kg, I.P.) was administered daily for 7 days. Subsequently, Para (20.5 mg/kg) and Azil (5 mg/kg) were given orally, while SIS3 (2 mg/kg, I.P.) was administered for 7 days. Serum and urine renal function markers were measured. Renal histopathology, protein expression of TGF-β1, CTGF, Smad3, Smad2 and Smad7, and gene expression of miRNA-21 and miRNA-200b were evaluated. Results GM caused significant ( p < 0.001) nephrotoxicity with elevated BUN, serum creatinine, urinary albumin/creatinine ratio, and KIM-1 and increased fibrosis and marked type I collagen deposition compared to normal control. However, treatments with Para & Azil resulted in significant ( p < 0.05) improvement in renal functions. Pro-fibrotic markers TGF-β1, connective tissue growth factor (CTGF), Type I Collagen, Smad 2 and Smad3 were reduced, while Smad7 was increased in treated groups versus GM group. Additionally, miRNA-21 was downregulated and miRNA-200b was upregulated following treatments. Conclusion Paraxanthine and azilsartan demonstrated significantl restoring of kidney function and suppressing fibrotic progression. Their actions were mediated through regulation of Smad3/7 signaling and modulation of miRNA-21 and miRNA-200b expression, highlighting these pathways as promising therapeutic targets for the treatment of renal fibrosis.

问 AI

Bookmark

View Full Paper